EmbryoSure The Next Generation PGT-A Screening Services
Understanding the EmbryoSure Difference
Standard PGT-A (PGS) typically only checks the number of chromosomes. Within our Preimplantation Genetic Testing framework, EmbryoSure is a proprietary solution that integrates two powerful technologies, Copy Number Variation (CNV) and Single Nucleotide Polymorphism (SNP) analysis using advanced Next-Generation Sequencing (NGS).
Performed as an EmbryoSure test in our clinical genetic lab, this dual-layer approach allows us to detect complexities that standard tests often miss — helping to identify embryos with higher genetic viability.
Understanding the Origin of Aneuploidy
Unlike standard PGT-A, EmbryoSure goes a step further by analysing the origin of aneuploidy — identifying whether the chromosomal abnormality arises from the maternal or paternal side. This is enabled through advanced SNP-based analysis that provides deeper insight into chromosomal patterns beyond standard screening.
Understanding where aneuploidy originates provides deeper clinical insight into the underlying causes of poor embryo development. It helps fertility specialists tailor treatment strategies, optimise stimulation protocols, and make more informed decisions for future IVF cycles.
By moving beyond detection to interpretation, EmbryoSure enables a more precise and personalised approach to embryo selection and fertility care.

Who is EmbryoSure Recommended For?
The EmbryoSure Process
Dual-Method Analysis (CNV + SNP)
Precise Haploid & Triploid Detection
Maternal Cell Contamination (MCC) Screening
One of the biggest risks in genetic testing is the accidental presence of the mother’s cells in the biopsy sample. EmbryoSure includes a proprietary contamination check — ensuring the results reflect the embryo’s genetics, not the mother’s.
Sibling & Genetic Pool Verification
Ready for a Smarter Path to Parenthood?
Discover how EmbryoSure can transform your fertility journey with unmatched genetic clarity.